Robert Schooley

Robert SchooleyDr. Schooley began his research career studying the immunopathogenesis of herpesvirus infections in immunocompromised patients, but shifted his focus to AIDS in 1981 when the first cases of this syndrome began to appear in Boston. His research group was among the first to delineate the humoral and cellular immune responses to HIV infection. Over the next 15 years he became increasingly involved in the discovery and development of antiretroviral chemotherapeutic agents including reverse transcriptase inhibitors, protease inhibitors and entry inhibitors. He was recruited to the University of Colorado Health Sciences Center in 1990 to serve as Head of the Division of Infectious Diseases. While at Colorado, he was elected to serve as Chair of the NIAID’s AIDS Clinical Trials Group (ACTG) which he headed from 1995 – 2002. During his tenure as Group Chair, the ACTG expanded to include research sites in Latin America, the Caribbean, South Asia and Africa and is now the largest and most productive multinational clinical and translational research organization focusing on the pathogenesis and therapy of HIV and its complications. Currently, Dr. Schooley's personal research interests include HCV, influenza and HIV pathogenesis, and therapy and infections that cause morbidity and mortality in resource limited settings.